Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2019-01-04 Director's Dealing
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
Director's Dealing 2019
Director's Dealing
2019-01-04 English
Director's Dealing 2018
Director's Dealing
2018-12-29 English
Director's Dealing 2018
Director's Dealing
2018-12-07 English
Regulatory Filings 2018
Regulatory Filings
2018-12-07 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It is not a financial report, earnings release, or management discussion. The document primarily serves as a regulatory filing to register securities for trading on an exchange (Nasdaq). It includes no financial statements or detailed financial data. The document length is 2779 characters, which is relatively short and consistent with a regulatory filing rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-12-06 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions the announcement of approval to list common stock on the Nasdaq Capital Market, and includes a press release as an exhibit. The document is short (2816 characters) and serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-12-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.